Gapping up
In reaction to strong earnings/guidance: MPO +32%, AMZG +8.7%, RVLT +8.3%, CUR +4.7%,CEL +3%, STML +3%, RDNT +2.9%, GURE +2.3%, CXDC +1%, PKOH +0.5%, AKBA +0.5%, .
M&A news: LTM +5.3% (confirms it has entered into definitive agreement to be acquired by affiliates of Leonard Green & Partners and TPG;Life Time Shareholders to receive $72.10 per share in cash),SLXP +2.7% (hearing chatter that VRX will raise its bid on SLXP to $173/share; currently the offer stands at $158, while ENDP has an offer for $175), VRX +1.2% (hearing chatter that VRX will raise its bid on SLXP to $173/share; currently the offer stands at $158, while ENDP has an offer for $175), .
Other news: OMEX +21% (enters into financing agreement with strategic investor for offshore mineral and resource exploration), MVIS +16.8% (received orders totaling $14.5 mln for components for its Fortune Global 100 customer), AMRN +12.1% (cont strength following Friday's move), CTIC +5.1% (announces publication in blood of Phase 2 results of Pacritinib in patients with myelofibrosis), ACRX+4.9% (initiation of pivotal Phase 3 trial for ARX-04, as treatment of acute pain), BSX +4.5% (receives FDA approval for WATCHMAN left atrial appendage closure device), ADXS +4.4% (presents preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate), NBS +4.2% (updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study), HBI+4.1% (will replace Avon Products (AVP) in the S&P 500), TLMR +3.2% (will replace Buffalo Wild Wings in the S&P SmallCap 600 ), HSIC +2.7% (will replace Carefusion (CFN) in the S&P 500), TSLA +2.3% (Elon Musk tweets 'Tesla press conf at 9am on Thurs about OTA software update. Affects entire Model S fleet'), SNY +2% (Sanofi-Aventis and Regeneron (REGN) announce 18-month results of ODYSSEY LONG TERM trial with Praluent published in The New England Journal of Medicine), SLG +2% (will replace Nabors Industries (NBR) in the S&P 500), SNY +2% (Sanofi-Aventis and Regeneron (REGN) announce 18-month results of ODYSSEY LONG TERM trial with Praluent published in The New England Journal of Medicine), EQIX +1.9% (will replace Denbury Resources (DNR) in the S&P 500), KKD +1.4% (modestly rebounding on light vol following last weeks earnings)
Analyst comments: BLPH +10.3% ( initiated with a Outperform at FBR Capital, among other firms),ITEK +7.7% (initiated with a Overweight at Piper Jaffray; initiated with a Buy at Nomura), KING +5.3% (upgraded to Overweight from Neutral at JP Morgan), FRAN +3.5% (upgraded to Buy from Neutral at Janney), JBLU +1.5% (upgraded to Outperform from Mkt Perform at Raymond James), WSTC +1.3% (upgraded to Outperform from Neutral at Robert W. Baird)
In reaction to strong earnings/guidance: MPO +32%, AMZG +8.7%, RVLT +8.3%, CUR +4.7%,CEL +3%, STML +3%, RDNT +2.9%, GURE +2.3%, CXDC +1%, PKOH +0.5%, AKBA +0.5%, .
M&A news: LTM +5.3% (confirms it has entered into definitive agreement to be acquired by affiliates of Leonard Green & Partners and TPG;Life Time Shareholders to receive $72.10 per share in cash),SLXP +2.7% (hearing chatter that VRX will raise its bid on SLXP to $173/share; currently the offer stands at $158, while ENDP has an offer for $175), VRX +1.2% (hearing chatter that VRX will raise its bid on SLXP to $173/share; currently the offer stands at $158, while ENDP has an offer for $175), .
Other news: OMEX +21% (enters into financing agreement with strategic investor for offshore mineral and resource exploration), MVIS +16.8% (received orders totaling $14.5 mln for components for its Fortune Global 100 customer), AMRN +12.1% (cont strength following Friday's move), CTIC +5.1% (announces publication in blood of Phase 2 results of Pacritinib in patients with myelofibrosis), ACRX+4.9% (initiation of pivotal Phase 3 trial for ARX-04, as treatment of acute pain), BSX +4.5% (receives FDA approval for WATCHMAN left atrial appendage closure device), ADXS +4.4% (presents preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate), NBS +4.2% (updated efficacy and safety results from the one-year follow-up for its Phase 2 PreSERVE study), HBI+4.1% (will replace Avon Products (AVP) in the S&P 500), TLMR +3.2% (will replace Buffalo Wild Wings in the S&P SmallCap 600 ), HSIC +2.7% (will replace Carefusion (CFN) in the S&P 500), TSLA +2.3% (Elon Musk tweets 'Tesla press conf at 9am on Thurs about OTA software update. Affects entire Model S fleet'), SNY +2% (Sanofi-Aventis and Regeneron (REGN) announce 18-month results of ODYSSEY LONG TERM trial with Praluent published in The New England Journal of Medicine), SLG +2% (will replace Nabors Industries (NBR) in the S&P 500), SNY +2% (Sanofi-Aventis and Regeneron (REGN) announce 18-month results of ODYSSEY LONG TERM trial with Praluent published in The New England Journal of Medicine), EQIX +1.9% (will replace Denbury Resources (DNR) in the S&P 500), KKD +1.4% (modestly rebounding on light vol following last weeks earnings)
Analyst comments: BLPH +10.3% ( initiated with a Outperform at FBR Capital, among other firms),ITEK +7.7% (initiated with a Overweight at Piper Jaffray; initiated with a Buy at Nomura), KING +5.3% (upgraded to Overweight from Neutral at JP Morgan), FRAN +3.5% (upgraded to Buy from Neutral at Janney), JBLU +1.5% (upgraded to Outperform from Mkt Perform at Raymond James), WSTC +1.3% (upgraded to Outperform from Neutral at Robert W. Baird)